Authorization & medical necessity required

Coverage and reimbursement for vaginitis diagnostic testing are subject to authorization and medical necessity; services must meet the member's benefit coverage at the time of request and follow applicable payer rules. Providers must confirm benefits and obtain any required authorizations prior to ordering tests.

Use molecular and POC tests when clinically indicated

Molecular (NAAT/TMA/qPCR) and point-of-care tests are described as clinically useful and may reduce downstream utilization and costs; order these tests when clinical evaluation indicates their use and in accordance with intended use described by the assay.

• Syndromic PCR testing associated with reduced follow-up visits and cost savings in population data.

Order FDA-cleared multiplex NAATs for symptomatic patients only

Some multiplex NAATs (e.g., BD MAX Vaginal Panel, Aptima assays, Xpert Xpress MVP) are FDA-cleared/approved for symptomatic women; order these assays consistent with their intended use (symptomatic patients) and platform labeling.

• Multiplex NAATs are intended for symptomatic women and not for asymptomatic screening or test-of-cure.

Codes provided for reference — no explicit prior auth stated here

The policy provides CPT/HCPCS procedure codes for reference but does not state an explicit prior authorization requirement for the listed codes in this excerpt; use the codes for billing alignment and verify plan-specific prior authorization rules.

• Example codes listed for reference include 81513, 81514, 0505U, 87800–87801, 87480–87482.

Prior authorization not specified in policy excerpts

No specific payer-level prior authorization requirements are specified in these policy excerpts; providers must rely on local plan rules and benefit checks to determine if authorization is required.

Minimum 7‑day retesting interval for multi-organism NAAT panels

NAAT panels that detect BV, VVC, and TV should not be repeated before a seven-day minimum treatment window has passed for organisms treated with up to seven-day regimens; if symptoms persist despite treatment, individual organism testing may be performed within this window.

• Do not repeat a multi-organism NAAT panel for all three vaginitis types sooner than 7 days after treatment initiation.

Use office tests first; use commercial labs if unavailable

Initial diagnostic evaluation should include office-based tests when available (vaginal pH, KOH whiff test, and wet mount microscopy); if these are unavailable, order appropriate commercial laboratory molecular or point-of-care tests.

• Office diagnostics (pH, KOH, microscopy) are acceptable first-line tests per CDC and ACOG guidance.
• Use commercial NAAT/TMA/qPCR assays when office testing is not available or to increase diagnostic accuracy.

Follow-up testing and retreatment — retest per clinical guidance

Follow-up testing and retreatment should be based on clinical circumstances: patients with persistent or recurrent symptoms should return for evaluation; for trichomoniasis, retesting is recommended approximately 3 months after treatment to detect reinfection.

• Retest sexually active women treated for trichomoniasis about 3 months after initial treatment per CDC/ACOG.
• Verify clinical status before retreatment or repeat testing.

Reference placeholder (no new action stated)

This chunk is a placeholder in the inventory; no additional explicit provider action is stated in the provided excerpt.

No step therapy requirements specified

No step therapy requirements are described in the provided text; providers should follow clinical guidance and payer-specific rules where applicable.

Submit accurate documentation and use proper coding

Providers must submit accurate documentation of services rendered and use appropriate industry-standard coding; failure to follow coding/billing guidelines or current reimbursement policies may result in claim denial or recoupment.

• Code claims per CPT, HCPCS, ICD-10, and CMS/NCCI guidance.
• Ensure documentation supports billed services.

Document history, exam, and specific lab testing

Document medical history, physical examination findings, and laboratory testing performed (vaginal pH, KOH whiff test, microscopy, or appropriate commercial molecular/POC tests) to support the clinical indication for testing.

• Record symptoms, sexual history, vaginal exam findings, and which diagnostic tests were performed.
• Note specimen type (clinician- or patient-collected vaginal swab) when using molecular assays.

LDTs must be validated and CLIA-compliant

Laboratory-developed tests (LDTs) are regulated under CLIA as high-complexity tests and must be validated by the performing laboratory; documentation of LDT validation and CLIA compliance may be required for their use.

• LDTs are not FDA-approved and require in‑house validation under CLIA '88.

Document specimen type and assay used (LDT or FDA-cleared)

When using specific LDTs or FDA‑cleared assays (e.g., Aptima BV, BD MAX Vaginal Panel), document the specimen type, that the clinical presentation is consistent with vaginitis, and any validation or platform details needed to support use.

• Specify clinician‑ or patient‑collected vaginal swab in documentation.
• Reference the specific assay (Aptima BV, BD MAX) used when reporting results.

No further documentation requirements specified here

No additional documentation requirements are specified in these excerpts beyond those already stated; bibliographic references are listed in the evidence section.

Risk of denial for incorrect coding or unsupported billing

Claims may be denied or recouped if coding/billing guidelines, reimbursement policies, or documentation requirements are not followed; misuse of procedure codes provided for reference may also trigger denials.

• Procedure codes in the policy are for reference and may not be all‑inclusive; verify correct coding before billing.

Document clinical evaluation to support testing

Failure to document a complete history, exam, and appropriate laboratory testing to determine the etiology of vaginal symptoms may lead to inappropriate management and potential claim denials; document findings to support the diagnostic choice.

• Document clinical signs, pH, microscopy results, and rationale for molecular testing if ordered.

Follow applicable government coverage policies when conflicts exist

When there is a conflict between this policy and applicable government policies (e.g., Medicare LCDs/NCDs or state Medicaid rules), determinations must follow the relevant government policy.

Procedure codes are reference only — verify before billing

Procedure codes listed in this Medical Policy are provided only as a general reference and may not be all‑inclusive; improper use of the listed codes or billing without supporting documentation could result in claim denials.

No explicit authorization or denial criteria present in these excerpts

These policy excerpts do not include explicit authorization or denial criteria; the section largely contains evidence references and guidance — verify plan-specific requirements and check benefits prior to ordering.